087 - Global Trends in Thrombectomy Device and Systems Development: Retrospective Review between 2000-2022
Hanzhou (Hanssen) Li, MD – IR/DR Resident Physician, Department of Radiology, Division of Interventional Radiology, Emory University SOM; Deepak Iyer, BS – Research Fellow, Department of Radiology, Division of Interventional Radiology, Emory University SOM; Zachary Bercu, MD – Associate Professor of Interventional Radiology, Department of Radiology, Division of Interventional Radiology, Emory University SOM
Purpose: Novel technologies have shaped modern techniques in endovascular thrombectomy to ultimately improve outcomes for high-risk or critically-ill patients. The purpose of our study was to examine global trends in thrombectomy device and systems development over the last two decades dating from 2000-2022.
Material and Methods: Global databases were accessed to compile a list of thrombectomy devices and systems submitted for regulatory approval by respective institutions and companies. Database query was between 01/01/2000 to 09/01/2022. Regulatory dossiers were examined, from which additional information including country of origin, product territory, indications for use, device mechanism of action, and stage of development were derived.
Results: Between the years 2000-2022, there were 161 thrombectomy devices and systems developed by 48 unique companies/institutions. 19 countries were represented with the largest global territories first in the United States, followed by China, and then Japan. Of these devices, 19.3% (31) are in product development, 2.5% (4) are in preclinical stages, 6.2% (10) are in the approval process, and 54.7% (88) are in clinical application. One product was entirely discontinued and an additional 16.1% (27) are inactive or indeterminate in stage of development. By indication, neurovascular indications accounted for 58.3% (93) of all indications, followed by general thrombosis 24.8% (40) and pulmonary embolism 9.3% (15). 29.2% (47) of devices were labelled as stent-retriever thrombectomy devices while the remaining 70.8% (114) were labeled as aspiration, manual aspiration, or thrombectomy systems devices.
Conclusions: Global trends in thrombectomy device and systems development favor neurovascular indications with mixed device mechanisms of aspiration versus stent retriever thrombectomy systems. The United States, China, and Japan represent the largest global territories, and there are a number of devices in the developmental pipeline from each of these major product territories.